STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
99
13F, latest reported quarter
Conversions, 180 days
43
Codes C/M, not in net · $2.1M priced
What the filings say about OMDA
Insiders, 180 days
-$7.6M net sold
4 sellers · 28% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$2.8M
13 notices
Omada Health insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Omada Health, Inc. insiders sold a net $7.6M of stock across 63 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Sep 10, 2026.
The trade is 3.3% of the 386,908 shares held after it.
3 other insiders sold within 30 days.
99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Duffy Sean P. sold about $266.8K of OMDA under a 10b5-1 plan on Oct 1, 2026; 3 other insiders sold within 30 days and 99 funds added in the latest 13F quarter.
23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Sep 10, 2026.
The trade is 1.1% of the 382,594 shares held after it.
3 other insiders sold within 30 days.
99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Duffy Sean P. sold about $90.2K of OMDA under a 10b5-1 plan on Oct 1, 2026; 3 other insiders sold within 30 days and 99 funds added in the latest 13F quarter.
6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Aug 12, 2026.
The trade is 1.2% of the 295,713 shares held after it.
3 other insiders sold within 30 days.
99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President Shao Wei-Li sold about $79.2K of OMDA under a 10b5-1 plan on Sep 10, 2026; 3 other insiders sold within 30 days and 99 funds added in the latest 13F quarter.
6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Aug 12, 2026.
The trade is 0.1% of the 295,313 shares held after it.
3 other insiders sold within 30 days.
99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President Shao Wei-Li sold about $9.0K of OMDA under a 10b5-1 plan on Sep 10, 2026; 3 other insiders sold within 30 days and 99 funds added in the latest 13F quarter.
18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Aug 27, 2026.
The trade is 3.6% of the 174,506 shares held after it.
3 other insiders sold within 30 days.
99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Cook Steven L. sold about $135.1K of OMDA under a 10b5-1 plan on Sep 10, 2026; 3 other insiders sold within 30 days and 99 funds added in the latest 13F quarter.
63 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
OMDA planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
SEAN DUFFY
Filed 2026-10-01
$269.4K
Steven Cook
Filed 2026-09-10
$146.2K
SEAN DUFFY
Filed 2026-09-10
$321.6K
WEI-LI SHAO
Filed 2026-09-10
$86.8K
CRAIG GRACEY
Filed 2026-09-09
$14.3K
OMDA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Oberweis Micro-Cap Fund
$22.2M position · as of 2026-06-30
1.4%
Small Cap Growth Fund
$55.8M position · as of 2026-07-31
1.0%
Small Cap Growth Fund
$4.9M position · as of 2026-05-31
0.9%
Loomis Sayles Small Cap Growth Portfolio
$3.0M position · as of 2026-06-30
0.8%
Loomis Sayles Small Cap Growth Fund
$19.0M position · as of 2026-06-30
0.8%
American Century Small Cap Growth Insights ETF
$97.8K position · as of 2026-05-31
0.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $7.6M sold by insiders over 180 days, 99 funds added last quarter, $2.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$309.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM OMDA
FY Dec 2025
$260.2M
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
$87.8M
Mar 2026
$78.0M
Dec 2025
$75.8M
Sep 2025
$68.0M
Jun 2025
$61.4M
Mar 2025
$55.0M
Dec 2024
$48.0M
Sep 2024
$45.5M
At each fiscal year end
Single quarter
Net margin, TTM
+1.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM OMDA
FY Dec 2025
-4.9%
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
+6.0%
Mar 2026
-3.8%
Dec 2025
+6.8%
Sep 2025
-4.7%
Jun 2025
-8.7%
Mar 2025
-17.2%
Dec 2024
-17.2%
Sep 2024
-20.3%
At each fiscal year end
Single quarter
Free cash flow, TTM
$22.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM OMDA
FY Dec 2025
$16.9M
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
$3.9M
Mar 2026
-$11.9M
Dec 2025
$21.2M
Sep 2025
$9.6M
Jun 2025
$2.6M
Mar 2025
-$16.4M
Dec 2024
-$6.7M
Sep 2024
$980.0K
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2025-12-31 (6 months older than the period end); equity 2026-06-30
Debt to equity OMDA
FY Dec 2025
0.00x
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
0.00x
Mar 2026
0.00x
Dec 2025
0.00x
Sep 2025
0.00x
Jun 2025
0.14x
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt OMDA
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
-0.62x
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+1.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity OMDA
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
+1.8%
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+1.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets OMDA
FY Dec 2025
-5.6%
FY Dec 2024
-31.2%
FY Dec 2023
n/a
Jun 2026
+1.4%
Mar 2026
-2.1%
Dec 2025
-5.6%
Sep 2025
-9.1%
Jun 2025
-10.6%
Mar 2025
-24.9%
Dec 2024
-31.2%
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
-4.2%
operating income after a 0.0% effective tax rate, over long-term debt only, 2025-12-31 (6 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital OMDA
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
-4.2%
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-0.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed OMDA
FY Dec 2025
-7.3%
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
-0.2%
Mar 2026
-3.6%
Dec 2025
-7.3%
Sep 2025
-10.3%
Jun 2025
-11.6%
Mar 2025
-35.1%
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
83.65x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing OMDA
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
95.43x
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$956.1M
market value at close 2026-10-26 on 2026-08-04 shares, plus long-term debt only, 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
Enterprise value OMDA
FY Dec 2025
$691.8M
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
$1.1B
Mar 2026
$528.9M
Dec 2025
$691.8M
Sep 2025
$1.1B
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+1.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield OMDA
FY Dec 2025
+1.9%
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
+1.7%
Mar 2026
+2.9%
Dec 2025
+1.9%
Sep 2025
-0.9%
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing OMDA
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
OMDA ranks highest on financial health (99th percentile) and growth (90th), and lowest on risk and compliance (12th), among Healthcare Services peers.
Profitability
39
Inputs
Return on equity+1.8% · 54 pct, sector of 70
Return on assets+1.4% · 59 pct, sector of 88
Return on invested capital-4.2% · 1 pct, universe of 1,069
Return on capital employed-0.2% · 45 pct, sector of 68
Financial health
100
Inputs
Debt to equity0.00x · 100 pct, sector of 61
Cash flow to debtno debt to cover
Growth
90
Inputs
Revenue growth, YoY+53.2% · 90 pct, sector of 87
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
18
Inputs
Net Form 4 buying (codes P and S), 180d-$5.9M · 37 pct, sector of 64
Insider buyers, 180d0 · 0 pct, sector of 64
Institutional and government
38
Inputs
Funds adding, latest quarter99 · 38 pct, sector of 73
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
12
Inputs
Short interest, % of float+16.4% · 12 pct, sector of 93
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
1 not measured: US patents
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
OMDA filings, in plain words
Are Omada Health insiders buying or selling OMDA?
In the 180 days to 2026-10-28, Omada Health insiders were net sellers, a net $7.6M across purchases and sales reported on Form 4, by 4 sellers.
Are there planned insider sales of OMDA?
Yes. 13 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $2.8M of stock; the latest, by SEAN DUFFY, was filed 2026-10-01.
Read the full summary
In the 180 days to 2026-10-28, Omada Health insiders were net sellers of OMDA, a net $7.6M across purchases and sales reported on Form 4 by 4 sellers. 28% of the 53 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 13 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $2.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.